AMGN

Amgen (AMGN) closed at $439.26, down 1.79% from the prior day, underperforming the S&P 500. The biotech giant is scheduled to report earnings on November 3, 2026, with projected EPS of $5.72 (up 1.42% YoY) and revenue of $9.93 billion (up 3.94% YoY). The stock trades at a Forward P/E of 19.5, below its industry average of 25.2, and currently holds a Zacks Rank of #3 (Hold).

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

VanEck Biotech ETF (BBH) has reached a 52-week high, rising 41.1% from its low, driven by positive Phase 3 results for Amgen and AstraZeneca's Tezspire treatment for eosinophilic esophagitis. The fund shows a positive weighted alpha of 44.96, suggesting potential for continued gains in the near term.

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x).

Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

Johnson & Johnson and Amgen have outperformed the broader market in 2026 despite facing near-term challenges. JNJ's medtech division struggles with its Impella heart pump facing safety concerns and recalls, but its innovative medicines segment and new products like OTTAVA robotic surgery system offer long-term growth.

Amgen faces regulatory pressure on Tavneos and patent losses on denosumab, but strong pipeline candidates like MariTide and established growth drivers like Tezspire and Tepezza support its outlook. Both companies maintain excellent dividend track records, making them solid long-term income investments.

Amgen has attracted investor attention with a +12.2% return over the past month, outperforming the S&P 500's +1.5% gain. The company shows solid fundamentals with expected earnings growth of +5% for the current fiscal year and +7.1% for the next year, along with consistent revenue growth projections of +5.7% and +3.2% respectively. However, with a Zacks Rank #3 (Hold) rating and a neutral valuation grade of C, the stock is expected to perform in line with the broader market in the near term.

Amgen (AMGN) closed at $434.03, up 1.86%, outperforming the S&P 500. The stock has gained 13.22% over the past month.

Upcoming Q3 2026 earnings are expected on November 3 with an EPS of $5.72 (+1.42% YoY) and revenue of $9.93 billion (+3.94% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.57, trading at a discount to its industry average. However, the Medical - Biomedical and Genetics industry ranks 153rd out of 250+ industries.

Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million.

However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating.

Amgen (AMGN), a major biotech company, receives a #3 (Hold) rating from Zacks with a B VGM Score. While the company faces declining sales from older drugs due to biosimilar competition and recent patent expirations for key products Prolia and Xgeva in 2025, momentum investors should note the stock's 9.5% gain over the past four weeks. Six analysts have raised earnings estimates in the last 60 days, with the consensus estimate increasing to $22.94 per share.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Amgen (AMGN) closed at $414.87, up 1.82%, outperforming the S&P 500's 0.6% gain. The biotech giant has risen 6.53% over the past month.

Upcoming earnings are projected at $5.7 per share with revenue expected at $9.92 billion. Full-year estimates suggest $22.94 EPS and $38.83 billion revenue, representing 5.04% and 5.65% growth respectively.

However, the stock holds a Zacks Rank #3 (Hold) with a recent 0.13% downward EPS estimate revision. Trading at a Forward P/E of 17.76, it trades at a discount to the industry average of 23.15.

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

Amgen stock gained 2.6% to close at $413.08, outperforming the broader market decline. The biotech giant is projected to report EPS of $5.69 (up 0.89% YoY) and revenue of $9.91 billion (up 3.68% YoY).

For the full year, consensus estimates project earnings of $22.94 per share and revenue of $38.81 billion. Amgen holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 17.55, trading at a discount to its industry average.

Amgen has recently been a trending stock, with shares down 7.8% over the past month compared to the S&P 500's +0.8% gain. The biotech company shows solid fundamentals with consistent earnings and revenue beat history, but the Zacks Rank #3 (Hold) rating suggests it may perform in line with the broader market in the near term. Current year earnings are expected to grow 5% with revenue growth of 5.6%, while the stock trades at par with peers based on valuation metrics.

Amgen (AMGN) declined 3.38% in the latest trading session, underperforming the broader market. While the company's upcoming earnings are projected to show modest growth with EPS of $5.69 (+0.89% YoY) and revenue of $9.91 billion (+3.68% YoY), analyst estimates have slightly declined by 0.15% over the past month. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.38, trading at a discount to its industry average, though its PEG ratio of 3.04 exceeds the industry average of 1.91.

At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic.

The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.

The coronary artery disease treatment landscape is rapidly evolving with 20+ pharmaceutical companies actively developing 22+ pipeline drugs. Key players including Roche, Verve Therapeutics, Amgen, and others are advancing therapies targeting residual cardiovascular risk through novel mechanisms such as Factor XI inhibitors, gene therapy, and anti-inflammatory approaches. Recent clinical trial progress includes positive Phase IIa results for vortosiran and Phase II initiation of SRSD107, signaling growing momentum in addressing high-risk CAD patients beyond conventional treatments.

Healthcare sector is experiencing a significant rebound, with ETFs hovering near 52-week highs driven by double-digit earnings growth expectations, positive clinical trial results, attractive valuations, and expanding GLP-1 adoption. Major pharmaceutical companies reported promising drug-trial outcomes in oncology, obesity, and rare diseases, while M&A activity surged to nearly $284 billion. The sector is benefiting from a rotation out of overcrowded AI/tech trades into defensive growth.

The article compares two healthcare sector ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on 27 pharmaceutical companies, and iShares Biotechnology ETF (IBB), which covers 243 biotech stocks. IBB has a lower expense ratio (0.44% vs 0.58%) and outperformed over the past year (37.7% vs 33.9% return), but PJP offers higher dividend yield (0.92% vs 0.16%) and lower volatility. The choice depends on investor risk tolerance and portfolio goals.

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.